NCT04908111 2026-04-06
A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1
Cancer Research UK
Phase 1/2 Suspended
Clinical Trials
13 trialsNCT07296809 2026-04-02
SKB500 Combinations in Patients With Small Cell Lung Cancer
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 2 Recruiting
NCT06809946 2026-03-30
DEFLECT I
University Medical Center Groningen
Phase 2 Not yet recruiting
NCT06897579 2026-03-23
Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Recruiting
NCT07469202 2026-03-13
CYTALUX Dose Extension Study
On Target Laboratories, LLC
Phase 4 Not yet recruiting
NCT05184712 2026-03-04
Phase 3 Clinical Study of AK112 for NSCLC Patients
Akeso
Phase 3 Active not recruiting
NCT06956001 2026-02-12
Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
Allist Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT06970639 2026-02-12
A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
Allist Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT07230405 2026-02-06
A Phase II Study of SKB571 in Patients With Lung Cancer
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 2 Recruiting
NCT04081688 2026-02-05
Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC
Rutgers, The State University of New Jersey
Phase 1 Terminated
NCT05816252 2026-01-27
MK-2870-003
Klus Pharma Inc.
Phase 2 Active not recruiting
NCT07367529 2026-01-26
A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Not yet recruiting
NCT07348211 2026-01-23
SIM0610-101
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1 Recruiting